N-acetylcysteine Plus Deferoxamine for Patients With Hypotension
Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure
Lead SponsorUniversidade do Extremo Sul Catarinens
StatusCompleted No Results Posted
Indication/ConditionHypotension Acute Renal Failure
Intervention/Treatmentacetylcysteine deferoxamine ...
Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.
N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
Inclusion Criteria: Patients admitted to the ICU Presenting hypothesion (MAP < 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion Exclusion Criteria: Age lower than 18 years old Chronic renal failure A known history of allergy to any of the study drugs Using n-acetylcysteine to paracetamol overdose Pregnant women Patients who used iodinated contrast medium Hemoglobin less than 6.5 mg/dl Cancer patients